Peer-reviewed veterinary case report
Survival factors for dogs with inguinal and perineal mast cell tumors
By Cahalane, Alane Kosanovich et al.·Published in Journal of the American Veterinary Medical Association·2004·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Prognostic factors for survival of dogs with inguinal and perineal mast cell tumors treated surgically with or without adjunctive treatment: 68 cases (1994-2002).
- Species:
- dog
Plain-English summary
A group of 68 dogs with skin tumors called mast cell tumors (MCTs) located in the inguinal (groin) and perineal (near the rear) areas underwent surgery, sometimes followed by additional treatments like radiation or chemotherapy. The study found that many dogs lived for over three years after treatment, with about 79% remaining tumor-free for at least a year. However, older dogs and those that had tumor recurrences tended to have shorter survival times. Overall, with proper treatment, these dogs can have survival rates similar to those with MCTs in other body parts.
People also search for: dog mast cell tumor treatment · inguinal tumor prognosis in dogs · perineal mast cell tumor survival rate
Abstract
OBJECTIVE: To determine the prognostic factors for survival and tumor recurrence in dogs with cutaneous mast cell tumors (MCTs) in the perineal and inguinal regions treated surgically with or without adjunctive radiation therapy, chemotherapy, or both. DESIGN: Retrospective study. ANIMALS: 68 dogs. PROCEDURE: Medical records of dogs with histologically confirmed MCTs in the perineal region, inguinal region, or both treated surgically with or without adjunctive radiation therapy, chemotherapy, or both were reviewed. RESULTS: Mean tumor-free interval was 1,635 days (median not reached), and 1- and 2-year tumor-free rates were 79% and 71%, respectively. Median survival time was 1,111 days (mean, 1,223 days), and 1- and 2-year survival rates were 79% and 61%, respectively. Factors that negatively influenced survival time were age at diagnosis, tumor recurrence, and treatment with lomustine. CONCLUSIONS AND CLINICAL RELEVANCE: Results indicated that dogs with MCTs in the inguinal and perineal regions, if appropriately treated, may have survival times and tumor-free intervals similar to dogs with MCTs in other locations.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/15328716/